loading
前日終値:
$1.40
開ける:
$1.43
24時間の取引高:
2.60M
Relative Volume:
1.10
時価総額:
$121.97M
収益:
-
当期純損益:
$-37.34M
株価収益率:
-1.0331
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
+8.53%
1か月 パフォーマンス:
+26.13%
6か月 パフォーマンス:
+14.75%
1年 パフォーマンス:
-4.11%
1日の値動き範囲:
Value
$1.35
$1.45
1週間の範囲:
Value
$1.265
$1.47
52週間の値動き範囲:
Value
$0.772
$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
名前
Sellas Life Sciences Group Inc
Name
セクター
Healthcare (1155)
Name
電話
(646) 200-5278
Name
住所
7 TIMES SQUARE, NEW YORK, NY
Name
職員
15
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SLS's Discussions on Twitter

SLS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.405 121.97M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
494.55 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
608.93 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
618.41 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.13 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.53 24.70B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-07-21 開始されました Cantor Fitzgerald Overweight
2018-11-01 開始されました Oppenheimer Outperform
2018-04-02 開始されました H.C. Wainwright Buy
2018-03-19 アップグレード Maxim Group Hold → Buy

Sellas Life Sciences Group Inc (SLS) 最新ニュース

pulisher
08:46 AM

SELLAS Unveils Breakthrough Preclinical Data Highlighting - GlobeNewswire

08:46 AM
pulisher
08:45 AM

Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan

08:45 AM
pulisher
Apr 25, 2025

SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 25, 2025
pulisher
Apr 24, 2025

Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Loop Capital analysts downgrades a Sell rating for Canadian National Railway Co (CNI) - knoxdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

Analysts Are Recommending SELLAS Life Sciences Group Inc (SLS) As A Buy Candidate - Marketing Sentinel

Apr 21, 2025
pulisher
Apr 18, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 09, 2025

SELLAS reports promising AML treatment trial results - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan

Apr 08, 2025
pulisher
Apr 05, 2025

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 21, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 21, 2025
pulisher
Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 08, 2025

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World

Mar 08, 2025
pulisher
Feb 27, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 26, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register

Feb 26, 2025
pulisher
Feb 22, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Feb 22, 2025
pulisher
Feb 21, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq

Feb 20, 2025
pulisher
Feb 12, 2025

SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle

Feb 12, 2025
pulisher
Feb 10, 2025

SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025

Sellas Life Sciences Group Inc (SLS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
大文字化:     |  ボリューム (24 時間):